Cargando…
ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated with a relatively poor prognosis. The majority of...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998231/ https://www.ncbi.nlm.nih.gov/pubmed/21152077 http://dx.doi.org/10.1371/currents.RRN1202 |
_version_ | 1782193348017127424 |
---|---|
author | Allingham-Hawkins, Diane Lea, Andrew Levine, Susan |
author_facet | Allingham-Hawkins, Diane Lea, Andrew Levine, Susan |
author_sort | Allingham-Hawkins, Diane |
collection | PubMed |
description | Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated with a relatively poor prognosis. The majority of NSCLC patients present with advanced disease and have an average 5-year survival rate of 5%. Currently, the standard of care for NSCLC includes treatment with a platinum-based chemotherapy regimen. However, not all patients benefit equally from such treatment. Therefore, recent pharmacogenomic studies have been performed in order to identify specific biomarkers that may allow for patient-tailored treatment strategies. One such biomarker is expression of the excision repair cross-complementation group 1 protein, ERCC1. |
format | Text |
id | pubmed-2998231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29982312010-12-08 ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer Allingham-Hawkins, Diane Lea, Andrew Levine, Susan PLoS Curr Evidence on Genomic Tests Worldwide, lung cancer accounts for approximately 1 million deaths each year, making it the most common cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is often associated with a relatively poor prognosis. The majority of NSCLC patients present with advanced disease and have an average 5-year survival rate of 5%. Currently, the standard of care for NSCLC includes treatment with a platinum-based chemotherapy regimen. However, not all patients benefit equally from such treatment. Therefore, recent pharmacogenomic studies have been performed in order to identify specific biomarkers that may allow for patient-tailored treatment strategies. One such biomarker is expression of the excision repair cross-complementation group 1 protein, ERCC1. Public Library of Science 2010-12-06 /pmc/articles/PMC2998231/ /pubmed/21152077 http://dx.doi.org/10.1371/currents.RRN1202 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Evidence on Genomic Tests Allingham-Hawkins, Diane Lea, Andrew Levine, Susan ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer |
title | ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer |
title_full | ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer |
title_fullStr | ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer |
title_full_unstemmed | ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer |
title_short | ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer |
title_sort | ercc1 expression analysis to guide therapy in non-small cell lung cancer |
topic | Evidence on Genomic Tests |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998231/ https://www.ncbi.nlm.nih.gov/pubmed/21152077 http://dx.doi.org/10.1371/currents.RRN1202 |
work_keys_str_mv | AT allinghamhawkinsdiane ercc1expressionanalysistoguidetherapyinnonsmallcelllungcancer AT leaandrew ercc1expressionanalysistoguidetherapyinnonsmallcelllungcancer AT levinesusan ercc1expressionanalysistoguidetherapyinnonsmallcelllungcancer |